Endocardial Approach for Substrate Ablation in Brugada Syndrome by Tauber, Pablo E. et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Endocardial Approach for Substrate Ablation in
Brugada Syndrome
Pablo E. Tauber, Virginia Mansilla, Pedro Brugada,
Sara S. Sánchez, Stella M. Honoré, Marcelo Elizari,
Sergio Chain Molina, Felix A. Albano,
Ricardo R. Corbalán,
Federico Figueroa Castellanos and
Damian Alzugaray Bioeng
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/intechopen.75932
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original work is properly cited. 
Pablo E. Tauber, Virginia Mansilla, Pedro Brugada, 
r   .  , t ll   .  r , r l   li ri, 
         
icar   .  r alá , Federico Figueroa Castellanos 
and Damian Alzugaray Bioeng
Additional information is available at the end of the chapter
Abstract
Radiofrequency ablation (RFA) in Brugada syndrome (BrS) has been performed by both 
endocardial and epicardial. The substrate in BrS is not completely understood. We inves-
tigate the functional endocardial substrate and its correlation with clinical, electrophysio-
logical and ECG findings in order to guide an endocardial ablation. Two patients agreed to 
undergo an endocardial biopsy and the samples were examined with transmission electron 
microscopy (TEM) to investigate the correlation between functional and ultrastructural 
alterations. About 13 patients (38.7 ± 12.3 years old) with spontaneous type 1 ECG BrS pat-
tern, inducible VF with programmed ventricular stimulation (PVS) and syncope without 
prodromes were enrolled. Before endocardial mapping, the patients underwent flecainide 
testing with the purpose of measuring the greatest ST-segment elevation for to be corre-
lated with the size and location of substrate in the electro-anatomic map. Patients under-
went endocardial bipolar and electro-anatomic mapping with the purpose of identify areas 
of abnormal electrograms (EGMs) as target for RFA and determine the location and size 
of the substrate. When the greatest ST-segment elevation was in the third intercostal space 
(ICS), the substrate was located upper in the longitudinal plane of the right ventricular 
outflow tract (RVOT) and a greatest ST-segment elevation in fourth ICS correspond with a 
location of substrate in lower region of longitudinal plane of RVOT. A QRS complex widen-
ing on its initial and final part, with prolonged transmural and regional depolarization time 
of RVOT corresponded to the substrate located in the anterior-lateral region of RVOT. A 
QRS complex widening rightwards and only prolonged transmural depolarization time 
corresponded with a substrate located in the anterior, anterior-septal or septal region of 
RVOT. RFA of endocardial substrate suppressed the inducibility and ECG BrS pattern dur-
ing 34.7 ± 15.5 months. After RFA, flecainide testing confirmed elimination of the ECG BrS 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the reative
Comm s Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provi ed the original work is properly cited.
pattern. Endocardial biopsy showed a correlation between functional and ultrastructural 
alterations. Endocardial RFA can eliminate the BrS phenotype and inducibility during pro-
grammed ventricular stimulation (PVS).
Keywords: Brugada syndrome, radiofrequency catheter ablation, electrocardiography, 
mapping, biopsy
1. Introduction
Since the original publication in 1992 [1], many researchers have tried to explain the mecha-
nisms and substrate that causes an abnormal electrocardiographic (ECG) pattern and ventric-
ular arrhythmias in Brugada syndrome (BrS) and few therapeutic options have been found. 
Initially three hypotheses were proposed for explain the mechanism and arrhythmias in BrS, 
the abnormal repolarization theory [2], the abnormal depolarization theory [3] and the abnor-
mal expression of neural crest cells during cardiac development [4].
BrS is characterized by an elevated ST segment in the right precordial leads (V1–3) on the 
ECG and risk of sudden cardiac death (SCD) [1, 5]. The ECG 1 pattern is frequently intermit-
tent and can be unmasked by the administration of a sodium channel blocker (Figure 1). The 
incidence of SCD in subjects with Brugada type 1 ECG pattern and no previous cardiac arrest 
is 2 per 1000 patients per year [6, 7].
At present, there are just two therapeutic strategies, which include implantable cardioverter-
defibrillator (ICD) and/or chronic quinidine therapy [6, 7]. However, quinidine is not effective 
Figure 1. Characteristic BrS ECG. A. In the N°3 patient the ECG at baseline show spontaneous and intermittent type 1 
ECG BrS pattern. B. After flecainide test (400 mg, orally) [19].
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in many patients and its use is frequently associated with intolerable adverse effects. ICD 
implantation may be effective in preventing SCD, and is currently recommended as a class 
I indication for symptomatic patients with type 1 Brugada ECG pattern. Unfortunately, ICD 
therapy in many patients is associated with inappropriate shocks (overall ICD complication 
rate is 9.1% and inappropriate shocks in BrS occur in 13.7%), lead fractures/failure, device 
infections and frequent ICD discharges by electric storms [6, 8, 9].
As an autosomal dominant disease with incomplete penetrance, BrS was initially linked to 
mutations in the SCN5A gene [9]. Currently, more than 450 pathogenic variants have been 
identified in 24 genes encoding sodium, potassium, and calcium channels or associated pro-
teins [10, 11]. Known BrS-susceptibility genes can only partially explain the clinically diag-
nosed cases; therefore, many patients (65–70%) remain “genetically unresolved” [8, 9]. For 
many years, BrS has been considered a purely electric disease even if, more recently some 
authors have shown the presence of morphological and functional abnormalities (regional 
conduction slow in the endocardium and epicardium), predominantly located in the right 
ventricle outflow tract (RVOT) [12–14].
Radiofrequency ablation (RFA) has recently emerged as a therapeutic option in BrS patients of 
high risk. RFA in two previous reports was effective in preventing ventricular fibrillation (VF) 
in BrS [15, 16]. Two studies have recently shown fractionated systolic electrograms (EGMs) in 
epicardium of RVOT and RF normalized the ECG pattern and prevented ventricular fibrilla-
tion and ventricular tachycardia (VT/VF) occurrence in a short follow-up [17, 18].
2. Study population and risk factors
The arrhythmic events occur in patients who presented spontaneous type 1 ECG BrS pattern 
and syncope of presumed arrhythmic origin, so both are considered high-risk factors [6]. The 
risk of SCD in patients without ICD is 2 per 1000 patients per year [6, 7]. But unfortunately, 
the possibility of survival out of hospital is low if the first symptom is the SCD.
We in a prospective single-center study consecutively included 13 caucasian patients when 
they presented all three high-risk criteria: (1) documented spontaneous type 1 BrS ECG pat-
tern, (2) syncope of probable arrhythmic cause (syncope was defined as a no traumatic and 
reversible loss of consciousness, and was considered of arrhythmic origin in the absence of 
a prodrome or triggering circumstances), (3) inducible VF with PVS [19]. These were associ-
ated with at least one of the following conditions: family history of SCD at age < 45 years, type 
1 BrS ECG pattern in family members, early repolarization pattern, and/or nocturnal agonal 
respiration [6, 9]. Structural heart disease, systemic diseases and phenocopies was ruled out in 
each case on the basis of clinical history and extensive evaluation with 2D Echocardiography, 
tilt test, brain computed tomography, 24-hour ambulatory ECG monitoring, HIV test, cox-
sackie and parvovirus B19 test, Chagas disease test, myocardial perfusion and cardiac nuclear 
magnetic resonance. All patients had 5 points according to the risk score model currently pro-
posed by Sieira et al. [20] (spontaneous type 1 ECG pattern =1 point, inducible VF =2 points 
and syncope =2 points). None had a history of SCD or documented spontaneous VT/VF and 
did not receive antiarrhythmic drugs. Patients were submitted to endocardial bipolar and 
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electroanatomic mapping and RFA. One month before of mapping and RFA, 10 patients 
accepted the implant of an ICD with class IIa indication [9]. Table 1 shows the clinical char-
acteristics of the study patients. About 13 patients with spontaneous type 1 ECG BrS pattern, 
symptomatic by syncope without prodromes, and VF induced during programed ventricular 
stimulation (PVS) were enrolled and completed the study protocol. Five males (38.5%) and 
eight females (61.5%), with an average age of 38.7 ± 12.3 years (range 19–58 years) were enrolled. 
Most patients (54%) had a family history of SCD and all patients experienced previous synco-
pal episodes without prodromes. In four patients (31%) nocturnal agonal respiration and fam-
ily history of ECG 1 BrS pattern were evident. All patients had a VRP ≤ 200 m (180 ± 13.6 ms). 
A QRS complex duration >120 ms in V1 or V2 leads (129.6 ± 27 ms) in six patients (46%) and a 
R wave with an amplitude ≥3 mm in aVR lead during flecainide testing (3 ± 1.4 mm) in seven 
patients (54%) was found. In five patients (38.5%) a HV interval to DI lead >55 ms (53.4 ± 21 ms), 
in three patients a QRS fragmentation (23%) and in two patients a J wave (15.4%) were present. 
Interestingly, during bipolar mapping after premature ventricular contractions (PVCs), alter-
nating T and J-wave and changes of the ST segment elevation were found (Figure 2).
Syncope constitutes an important diagnostic and therapeutic challenge in BrS. Approximately 
one-third of BrS patients present syncope. Some cases of syncope may be related to VF that 
terminates spontaneously. Vagal syncope is probably the most frequent cause of syncope in 
the BrS [21] and vagal hypertony may facilitate the onset of spontaneous VF in BrS [22]. Also 
symptoms suggesting of vagal syncope may also be observed in syncope of cardiac origin 
[23]. In our study, two patients (15%) after RFA had near-syncope with vaso-vagal prodrome 
and without arrhythmias in the ICD interrogation [19].
Figure 2. Endocardial mapping. A. The N° 3 patient in the peripheral zone of substrate show middle diastolic, pre-
systolic and continuous EGMs. The split pre-systolic potential (red arrows) triggers PVC (red star). B. After PVCs (red 
star), alternating T and J wave are shown (electric turbulence). Also displays spontaneous ST segment elevation changes 
(red arrows) [19].
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BrS is eight times more prevalent in males, probably for higher testosterone levels and a more 
prominent transient outward current (Ito). Males are at increased risk for developing a spon-
taneous type 1 ECG BrS pattern and VF during PVS. Nevertheless, because the majority of the 
asymptomatic patients are also male the gender is not an independent predictor of arrhyth-
mic events [9, 24]. It is striking that eight of our patients (61.5%) were females. Five of these 
had between 38 and 58 years of age and menopausal symptoms, so we might suspect that lack 
of estrogens could induce the expression of phenotype [19].
3. Electrophysiological study and mapping: identification of 
functional substrate
Nademanee et al., found prolonged and fractionated late potentials in the anterior zone of epi-
cardium of RVOT [17]. Recently, Brugada et al. in 14 inducible patients reported abnormal EGMs 
only in epicardium of the anterior free wall of right ventricle and in RVOT [18]. However, con-
sistently we find a substrate in the endocardium of RVOT and RFA eliminates abnormal EGMs, 
ECG BrS pattern and inducibility during a median follow-up of 44.7 ± 15.5 months in 13 patients. 
We saw the substrate not only in the anterior zone of RVOT but also in septal and lateral regions, 
but never in the posterior region [19]. Sunsaneewitayakul et al. reported late depolarization zones 
on the endocardial of RVOT. Endocardial RFA about these zones modified the ECG BrS pattern 
and suppress the VF storm [16]. Similarly, we reported areas with late depolarization, diastolic 
electrical activity and abnormal systolic EGMs. In our study high-density detailed endocardial 
electroanatomical and bipolar voltage mapping of right ventricle and RVOT was performed, 
using 3-dimensional (3D) mapping system En Site NavXTM under local anesthesia and seda-
tion, during stable sinus rhythm [19]. AH and HV interval to DI and V2 lead and ventricular 
refractory period (VRP) were measured. Bipolar EGMs were filtered from 10 to 400 Hz and dis-
played at 100–200 mm/s speeds. Systolic EGMs with an amplitude ≤1.5 Mv, split or fractionated 
whit a duration >80 ms and delayed components extending beyond the end of QRS complex 
and accompanied by late potentials (LPs) were defined as abnormal. The EGMs found in the 
diastole were referred as “diastolic electrical activity”. The number of diastolic EGMs (separated 
by isoelectric line) in two successive sinus cycles was counted. PVS of RVOT with 3 cycle lengths 
(600, 500 and 400 ms) and up to two premature extrastimuli was performed. Premature extra-
stimuli was decreased in 20 ms step until a coupling interval of 200 ms or the VRP was reached 
or VF lasting >10 seconds was induced. The induction with PVS up to two premature beats is 
independent predictors of poor prognosis with a high negative predictive value and was associ-
ated with increased risk, but has a controversial prognostic value. The lack of induction does not 
necessarily portend a low risk and hence clinical factors are the most important determinants [6, 
20, 25, 26]. VF inducibility rate is highest in patients with BrS and syncope of unknown origin 
(80%), the lowest in asymptomatic patients (61.5%), and intermediate in patients with vasovagal 
syncope (70.5%) [26–29]. However, it is important to note that these observations correspond to 
the pre-ablation era of BrS and therefore, the PVS could be a good predictor of outcome after RFA 
[18]. In our patients the endocardial RFA of diastolic electrical activity and abnormal systolic 
EGMs suppressed the type 1 ECG BrS pattern and inducibility with PVS, making the patients 
asymptomatic, as was previously reported for the epicardial RFA [17, 18].
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We identified three zones of substrate according to amplitude of the systolic EGMs: central 
very low voltage zone <0.5 mV, peripheral low voltage zone of 0.5–1.5 mV (border) and normal 
voltage zone >1.5 mV [19]. The central zone of substrate using filling scaling was measured 
in mm2 and located in the RVOT. Areas showing low-amplitude signals were mapped with 
greater point density. Abnormal endocardial electroanatomic voltage maps, characterized by 
very low-voltage EGMs with clean diastoles in the central area of substrate were found. Only 
three patients (23%) during bipolar mapping showed fragmented systolic EGMs of low-volt-
age (≤ 1.5 mV) with duration greater of 80 ms between central and peripheral zone (border 
zone) of voltage mapping. As shown in Figure 3, only in the peripheral zone of substrate the 
endocardial diastolic EGMs (mean 6.7 ± 1.4 EGMs in two successive sinus cycles) were pres-
ent. Overall, the median baseline very low voltage or central area of substrate (≤ 0.5 mV) was 
14.2 mm2 (SD = 10.5) (Table 1).
It is important to note, that epicardial mapping may not recognized a substrate located in the 
septal zone of RVOT. In addition, during epicardial mapping the interposition of fat tissue 
between the epicardium and the exploratory catheter could decrease the amplitude of the 
potentials recorded, giving false areas of low voltage. Our study only inclusion 13 patients 
and may be considered a small size sample [19]. However, our results are consistent allowing 
us to reach reliable conclusions. We not performed genetic studies. However, it is unlikely 
that this could affect our observations because mutations have been described in over 24 
genes and BrS-susceptibility genes can only partially explain the clinically diagnosed cases. 
Figure 3. Endocardial electroanatomic maps and location of abnormal EGMs. Double systolic EGMs, late potentials, 
middle diastolic potentials and continuous diastolic activity in peripheral zone that triggers PVCs is displays. Prolonged 
and fragmented systolic EGMs of low voltage in border zone in three patients can be observed. In the central zone of 
substrate observe clean diastole with very low-voltage systolic potentials. The N°3 patient displays single and split pre-
systolic potentials in peripheral zone of substrate which triggers PVCs [19].
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Patient 1 2 3 4 5 6 7 8 9 10 11 12 13 Total % Mean SD
Age 41 33 57 55 58 27 46 26 24 19 38 38 41 38.7 12.3
Sex M F F M F M M F F M F F F F = 8 M = 5 F = 61.5%-M = 38.5%
Spontaneous type 1 ECG pattern Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 13 100%
Syncope without prodromes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 13 100%
Nocturnal agonal respiration No No No No Yes No Yes No Yes No No Yes No 4 31%
Palpitations Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 13 100%
Family history SCD No No Yes Yes Yes No No Yes Yes Yes Yes No No 7 54%
Family history BrS No Yes No No No No No No Yes Yes Yes No No 4 31%
VRP ≤ 200 ms 180 180 160 200 160 180 200 180 160 180 180 200 180 13 100% 180 ms 13.6
QRS duration in V2 lead (> 120 ms) 160 105 120 180 120 120 140 100 90 140 170 140 100 6 46% 129.6 ms 27
R wave in aVR lead (≥ 3 mm) (#) 3 4.5 2 2.5 1.5 1 4 4 1.5 6 3 4 1 7 54% 3 mm 1.4
QRS fragmentation No Yes No No No No No Yes No No No No Yes 3 23%
J wave No No No No No No Yes No No No Yes No No 2 15.4%
HV interval to DI lead (>55 ms) 60 57 40 120 57 40 46 35 45 45 55 35 59 5 38.5% 53.4 ms 21
HV interval to V2 lead (>55 ms) 40 40 35 80 45 40 46 35 40 45 55 35 46 1 7.7% 44.8 ms 11.5
Follow-up (months) 66 63 56 53 51 54 45 46 45 43 28 12 19 13 100% 44.7 15.5
CDI implant No Yes Yes Yes Yes Yes No Yes Yes Yes Yes Yes No 10 77%
Biopsy No No No No No No No No No No Yes No Yes 2 15%
Very low-voltage AREA(≤ 0.5 mV) in (mm2) 23 8 19 42 5 4 8 10 19 10 8 25 4 13 100% 14.2 mm2 10.5
N° endocardial diastolic EGMs IN 2
successive cycles sinus (≥4 EGMs)
8 8 5 7 7 9 6 6 9 6 6 7 4 13 100% 6.7 1.4
Procedure time (min) 120 110 100 90 120 95 105 95 100 100 160 90 170 112 24.5
Fluoroscopy time (min) 15 10 10 10 15 10 12 13 12 10 27 10 25 13.7 5.5
M = male, F = female, SD = standard deviation, (#) = during flecainide test, VRP = ventricular refractory period.
Source: Ref. [19].
Table 1. Basal characteristic and risk factors.
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Although the results of mapping and RFA were good, we do not perform epicardial map-
ping and do not ignore the possibility that a portion of the substrate can remain present after 
ablation.
In addition, we found pre-systolic potentials as was previously reported by Haissaguerre et al. 
[15]. We showed with TEM Purkinje fibers in RVOT (Figures 2 and 3) [19]. These could be 
involved in the origin of pre-systolic potentials and genesis of early-onset PVCs that can trigger 
VT or VF, by spontaneous depolarization or micro-reentry circuit in the Purkinje network [30].
4. Electrocardiographic analysis
4.1. Size of substrate and ST-segment elevation
In the BrS the mechanism of ST segment elevation has been explained by the repolarization the-
ory (decreased of Na + and/or Ca++ channel function with a prominent Ito current in epicardium 
of RVOT generates a transmural voltage gradient), or the depolarization theory (disturbances in 
depolarization of RVOT can be cause of delayed conduction and ST segment elevation) [18, 20]. 
Nevertheless, the ECG changes are actually explained by the theorem of solid angle, where a 
substrate larger increases the magnitude of the ST segment elevation [31]. In 13 patients of high 
risk we have analyzed QRS complex duration, R wave amplitude in aVR lead, presence of frag-
mented QRS (f-QRS) and end-QRS slur or notch in DI, aVL, DII, DIII and aVF leads with J point 
peak ≥0.2 mv with descending ST segment, corresponding to an early repolarization or “J wave” 
[19]. Before of endocardial mapping the patients were underwent flecainide testing (400 mg, 
orally) with the purpose of measuring the greatest ST-segment elevation. The partial greatest 
ST-segment elevation in millimeters (ST-segment elevation in V1 + V2 leads in the third ICS and 
ST-segment elevation in V1 + V2 + V3 leads in fourth ICS), and total sum of greatest ST-segment 
elevation (ST segment elevation in V1 + V2 leads in the third ICS plus ST-segment elevation in 
V1 + V2 + V3 leads in fourth ICS) were measured. (Figure 4-A). Correlation between size and 
location of substrate in the electro-anatomic map and the ST-segment elevation were analyzed. 
As shown in Figure 4 and Table 2, with a cut-off ≥13 mm in the total sum of ST segment elevation 
two variants were found: (1) A total sum of ST-segment elevation <13 mm (n = 8, 61.5%, mean 
9.6 ± 1.3 mm) corresponded to a central area of substrate of 7.7 ± 1.8 mm2; (2) A total sum of ST 
segment elevation ≥13 mm (n = 5, 38.5%, mean 15 ± 1.1 mm) corresponded to a central area of 
substrate of 28.2 ± 9.2 mm2 (p < 0.001 for correlation of ST segment elevation and correlation of 
central area of substrate, with a value >0.90 of ROC curve).
Brugada et al. during electro-anatomic mapping with administration of a sodium channel 
blocker showed an increase in the size of the low voltage [18]. In concordance, our obser-
vations suggest that the total sum of ST segment elevation during flecainide testing would 
approximately determine the substrate size. In addition, the ECG leads with greater ST seg-
ment elevation would locate the substrate in the RVOT [19].
Morita et al. (145 patients who experienced syncope or had VF events) proposes ECG risk mark-
ers for the initial and recurrent episodes of VF in symptomatic patients with BrS. The f-QRS, 
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inferolateral early repolarization and complete RBBB were associated with occurrence of ven-
tricular tachyarrhythmia in the symptomatic patients [34]. Our population show in three patients 
a QRS fragmentation (23%) and in two patients a J wave (15.4%) [19].
4.2. Location of substrate in the longitudinal plane
Nademanee et al. found functional substrate in the anterior zone of epicardium of RVOT [17]. 
Brugada et al. in 14 inducible patients reported a functional substrate in epicardium of RVOT 
and anterior free wall of right ventricle [18].
In our study a high-density endocardial electroanatomical mapping of right ventricle and 
RVOT was performed [19]. Taking the pulmonary valve as upper limit and the supraven-
tricular crest as lower limit in the longitudinal plane the RVOT was divided in top and 
bottom. As shown in Figure 4-A and Table II, we have found three variants: (1) When the 
substrate was located in the top region of RVOT, it corresponded with the greater sum of 
ST-segment elevation in V1-V2 leads in the 3rd ICS (n = 5, 38.5%); (2) When the substrate was 
located in the bottom region of RVOT (n = 5, 38.5%), it corresponded with the greater sum of 
ST-segment elevation in V1-V2-V3 leads in the 4th ICS; (3) When the substrate was located in 
Figure 4. Correlation between ST segment elevation and substrate localization. A. With the administration of sodium 
channel blocker, a greater magnitude of total sum of ST segment elevation corresponds to a greater very low voltage 
area of substrate, and allows its location in the longitudinal plane of RVOT. (a) The location of the substrate in the 
bottom zone of RVOT correspond to a greater sum of ST segment elevation in fourth ICS vs. third ICS (5 vs. 3 mm). (b) 
The location of the substrate in the top zone of RVOT correspond to a greater sum of ST segment elevation in third ICS 
vs. 4th ICS (8 vs. 3 mm). (c) The location of the substrate in the intermediate zone of RVOT corresponds to a sum of ST 
segment elevation of equal magnitude in third ICS and fourth ICS (8 mm and 8 mm). B. The graph shows the correlation 
between linear increase of total sum of ST segment elevation and substrate size. The blue bars indicate each patient [19].
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Patient ST-segment with Total sum of 
ST-segment
Size of low 
voltage
Location of substrate
>elevation (mm) Elevation (mm) Area (mm2) In the longitudinal and
V1-V2 leads V1-V2-V3 
leads
Third ICS 4TH ICS
Transverse plane
V1 = 2 V1 = 2
1 V2 = 4 V2 = 7 16 36 Bottom
V3 = 1 Anterior-lateral
V1 = 3 V1 = 1
2 V2 = 4 V2 = 2 10 8 Top
V3 = 0 Anterior-lateral
V1 = 2 V1 = 3
3 V2 = 3 V2 = 5 14 19 Bottom
V3 = 1 Anterior-lateral
V1 = 2 V1 = 1
4 V2 = 6 V2 = 5 16 42 Intermediate
V3 = 2 Anterior-lateral
V1 = 2 V1 = 2
5 V2 = 1 V2 = 2 8 5 Bottom
V3 = 1 Anterior-lateral
V1 = 2 V1 = 0
6 V2 = 2 V2 = 2 8 5 Intermediate
V3 = 2 Anterior
V1 = 1 V1 = 1
7 V2 = 3 V2 = 4 10 8 Bottom
V3 = 1 Septal
V1 = 3 V1 = 1
8 V2 = 5 V2 = 2 11 10 Top
V3 = 0 Anterior
V1 = 2 V1 = 3
9 V2 = 3 V2 = 4 13 19 Bottom
V3 = 1 Anterior-septal
V1 = 5 V1 = 1
10 V2 = 3 V2 = 2 11 10 Top
V3 = 0 Anterior
Cardiac Arrhythmias130
the intermediate region of RVOT (n = 3, 23%), the sum of ST-segment elevation was of equal 
magnitude in the 3rd and 4th ICS (n = 3, 23%).
4.3. Location of substrate in the transverse plane
In our study during endocardial electroanatomical mapping, in the transverse plane an ante-
rior, lateral, posterior and septal areas were identified [19]. During endocardial bipolar map-
ping, the regional depolarization time (RDT) from the endocardial EGM of right ventricular 
inflow tract (RVIT) recorder by the catheter located at the site of His, until the beginning of 
endocardial EGM of RVOT, recorded by the catheter located in the RVOT was measured. A 
value from 0 to 10 ms was considered normal. Moreover, the trans-mural depolarization time 
(TDT) of RVOT from the beginning of endocardial EGM of RVOT until the end of QRS complex 
in V2 lead was measured. The TDT measured at DI was considered as normal value. As shown 
in Figure 5, we have found two variants were found: (1) When the substrate was located in 
the anterior lateral region of RVOT (n = 5, 38.5%), the HV interval measured to DI lead (mean 
70.6 ± 24 ms) was longer than the HV interval to V2 lead (mean 50 ± 15 ms). This was accom-
panied with widening of the QRS complex in its initial and final parts (widening of QRS left 
and right) in V1 and V2 lead. We defined this as “mixed delay of depolarization of RVOT”. 
Patient ST-segment with Total sum of 
ST-segment
Size of low 
voltage
Location of substrate
>elevation (mm) Elevation (mm) Area (mm2) In the longitudinal and
V1-V2 leads V1-V2-V3 
leads
Third ICS 4TH ICS
Transverse plane
V1 = 2 V1 = 1
11 V2 = 6 V2 = 2 11 8 Top
V3 = 0 Septal
V1 = 2 V1 = 1
12 V2 = 3 V2 = 2 8 8 Top
V3 = 0 Anterior-septal
V1 = 3 V1 = 3
13 V2 = 4 V2 = 5 15 25 Intermediate
V3 = 0 Anterior
Mean and SD 3 ± 1.3 2.3 ± 1.5 <13 (n = 8, 61.5%) 
9.6 ± 1.3
7.7 ± 1.8
≥13 (n = 5, 38.5%) 15 ± 1.1 28.2 ± 9.2
p value <0.001 <0.001
Source: [19].
Table 2. Correlation between sum of ST-segment elevation, location and size of low voltage area.
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Simultaneously, TDT and RDT were prolonged, because early depolarization of RVOT occurs. 
(2) When the substrate was located only in the anterior part (30.8%), or anterior-septal (15.4%) 
or exclusively in the septal region (15.4%) of RVOT, the HV interval measured to DI and V2 
leads showed no increase in its duration (mean 42.6 ± 6 ms and 41 ± 6.5 ms, respectively) and 
the widening of QRS was only rightward (widening QRS rightward). Moreover, the endo-
cardial EGM of RVIT and RVOT, and beginning of QRS complex in DI-V1-V2 lead they were 
activated simultaneously, indicating that there is no RDT delay, while TDT of RVOT was pro-
longed of dynamic manner. We defined this as “end delay depolarization of RVOT”.
Was report that 11% of patients with BrS have early repolarization pattern in the inferior-lateral 
leads and a more severe phenotype [32]. Interestingly, as shown in Figure 6 we found in two 
patients who had a substrate of exclusively septal location, showed end-QRS notching or slur-
ring pattern. When the substrate was located in the bottom-septal zone of RVOT (patient N°7) 
only end-QRS notch in aVL lead and slurred S-wave in DII, DIII and a VF leads was observed 
(Figure 6-A). Whereas, when the substrate was located in the top-septal zone of RVOT (patient 
N°11) an end-QRS slur in DI and aVL leads was observed (Figure 6-B). Our observations suggest 
that a location of substrate in septal region of RVOT, with beginning of the depolarization at the 
Figure 5. Location of substrate in transverse plane of RVOT. A. The N°4 patient displays a substrate located in the 
anterior-lateral zone of RVOT which corresponds to a widening of QRS complex to left and right. The HV interval to DI 
lead is longer (120 ms) that the HV interval to V2 lead (80 ms), while RDT and TDT are prolonged. B. The N°11 patient 
displays a substrate located in the septal zone of RVOT which correspond only to a widening of end QRS complex. The 
HV interval to DI and V2 leads is equal (55 ms) and only TDT is prolonged [19].
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endocardium correlated with the presence of end-QRS notching or slurring pattern in inferior 
or/and lateral leads by slow conduction. As shown in Figure 6 A and B the endocardial RFA of 
substrate produced their disappearance [19]. Normally the epicardium is electropositive with 
respect to electronegative endocardium creating a current flow of endocardium to epicardium. 
When activation spreads from endocardium to epicardium, in a context of slow conduction, the J 
wave coincides with the notch in the epicardial AP mediated by the Ito current and it is recorded 
by ECG. Conversely, when the activation begins in the epicardium, the J wave disappears hid-
den by the QRS complex [33]. Consequently, our observations lead us to think that the J wave 
depends more of late depolarization that early repolarization as was suggested by other authors.
5. Effects of RFA on the ECG BrS pattern and substrate
Endocardial and epicardial RFA has been proposed as a new strategy to prevent SCD and 
VT/VF in BrS patients of high risk. Nademanee et al. found what RFA on prolonged and 
Figure 6. RFA effects on the ECG. A. The N°7 patient displays a substrate located in bottom septal zone of RVOT. Before 
RFA a type 2 ECG BrS pattern, end-QRS notch in aVL lead and slurred S wave in DII, DIII and aVF leads are present. 
It disappears after RFA (red arrows). B. The N°11 patient displays a substrate in the top septal zone of RVOT. Before 
RFA a type 1 ECG BrS pattern and end-QRS slur in DI and aVL leads are present. It disappears after RFA (red arrows). 
C. Before RFA the flecainide test showed a type 1 ECG BrS pattern. The QRS complex duration in V1 and V2 leads was 
180 ms, while in DI was 90 ms (red lines). Immediately after ablation, the duration of QRS complex in V2 lead decreased 
to 90 ms and ECG BrS pattern disappears (red arrows). After RFA the flecainide test not induced type 1 ECG BrS pattern. 
The ECG at 3.8 years follow-up persist normal [19].
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fractionated late potentials in the anterior zone of epicardium of RVOT normalized the ECG 
BrS pattern and prevented VT/VF in all but one patient during a follow-up of 20 ± 6 months 
[17]. Recently, Brugada et al. in 14 inducible patients reported abnormal EGMs only in epi-
cardium of the anterior free wall of right ventricle and in RVOT. RFA eliminated both ECG 
BrS pattern and inducibility, with a median follow-up of 5 months [18].
In our study, the endocardial RFA in 13 patients resulted in normalization of the ECG BrS 
pattern, disappearance of end-QRS notching or slurring and suppression of inducibility in 
all patients during a mean follow-up of 47.7 ± 15.5 months (Table 1) [19]. About 30 days after 
RFA a flecainide testing did not develop ECG BrS pattern. Seven patients who entered to 
procedure with spontaneous type 1 ECG pattern showed ECG normalization at the end of 
the procedure. Immediately after RFA was applied, activity and varying degrees of changes 
in ST segment were observed. With following applications of RFA the ECG pattern pro-
gressively decreased (Figure 7). After RFA local abnormal diastolic EGMs completely disap-
pear and systolic EGMs were replaced by residual very low voltage areas. The mean time 
of procedure and fluoroscopy were 112 ± 24.5 and 13.7 ± 5.5 minutes, respectively (Table I). 
Postprocedure, predischarge, and follow-up 12-lead ECG confirmed the absence of BrS ECG 
pattern (Figure 6C). The patients were asymptomatic and free of arrhythmic events in the 
24-hour ambulatory ECG monitoring and in follow-up the ICD interrogation. Two patients 
(15%) had a near-syncope with prodrome at 24 of 46 months and at 18 of 36 months of 
follow-up respectively, without arrhythmias in ICD interrogation.
Sunsaneewitayakul et al. reported that endocardial RFA on the late depolarization zones 
modified the ECG BrS pattern in three patients and suppress the VF storm in four patients, 
during follow-up of 12–30 months [16]. Similarly, we obtained suppression of inducibility, 
normalization of BrS ECG pattern and early repolarization pattern with endocardial RFA of 
Figure 7. Effects of radiofrequency ablation on ECG. In the N°3 patient during endocardial RFA, intense activity 
and varying degrees of ST segment changes are shown. The ECG pattern progressively decreases with the following 
applications (red arrows). After RFA the local abnormal diastolic EGMs completely disappeared and systolic EGMs were 
replaced by residual low voltage areas [19].
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areas with late depolarization, diastolic electrical activity and abnormal systolic EGMs [19]; 
probably by substrate homogenization and transmural lesion of the thin wall of RVOT (mean 
3 mm). In addition, as show Figures 2 and 3 we found pre-systolic potentials as was previ-
ously reported by Haissaguerre et al. [15]. In our patients the endocardial RFA of these poten-
tials suppress PVCs and inducibility on PVS [19].
6. Correlation between functional and ultrastructural substrate
Coronel et al. show in a heart explanted of a BrS patient, fibrosis with epicardial fat infiltration 
as well as conduction slow without transmural repolarization differences [35]. Furthermore, 
interstitial fibrosis, fat tissue and myocyte disorganization with reduced gap junction expres-
sion in the presence of fractionated and unfractionated low voltage systolic EGMs in the 
endocardium and epicardium of RVOT was reported with optical microscopy [36–38].
In two patients, before RFA and after right internal jugular venous access through a steer-
able sheath we advanced a bioptome to RVOT and connected to 3-dimensional (3D) mapping 
system [19]. Guiding by electroanatomic and voltage map two samples of endo-myocardial 
biopsies of the three previously defined zones of substrate was obtained. Samples were fixed in 
4% glutaraldehyde and 0.1% sodium phosphate (pH 7.4) for transmission electron microscopy 
(TEM) study as was described previously [39]. As show Figure 8 the ultrastructural substrate 
and functional substrate were correlated [19]. In the Figure 8A, the patient N°13 in (a), (d) 
and (g) shows electro-anatomic and voltage map (functional substrate) with a central area of 
substrate of 25 mm2 located in the intermediate-anterior zone of the RVOT and the bioptome 
Figure 8. Correlation between functional and ultrastructural substrate. On the left side the electro-anatomic and 
voltage map (functional substrate) and bioptome connected to the navigation system is shown. On the right side the 
ultrastructural substrate is shown. Scale Barr: 3.33, 2.2 and 1.42 μm; mitochondria (mi); myofibrils (mf); Purkinje cell 
(pc); myofibrillar rests (*); lipofusin deposit (ld); intercalated disk (id); remains of erythrocytes (er) [19].
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connected to the navigation system. In (b) and (c) on the right side can be seen the ultra-
structural substrate which corresponds to normal zone with mitochondria, myofibrils, and a 
Purkinje cell of normal characteristics. In contrast, in the peripheral zone of substrate (e and f) 
note that when approaching to pathological area, cytoplasmic vacuolization, myofibrillar and 
mitochondrial disorganization with myofibrillar residue can be observed. The (h) and (i) corre-
sponds to the central zone, which depicts strong vacuolization and cell destruction with intense 
cytoplasmic disorganization and myofibrillar residue. In the Figure 8B, the patient N° 11 in 
(a), (d) and (g) shows the voltage and electro-anatomic map (functional substrate) with central 
area of substrate of 8mm2 located in the top-septal zone of the RVOT. In (b) and (c) on the right 
side can be seen the ultrastructural substrate which corresponds to normal zone with normal 
characteristics of mitochondria, myofibrils, and a Purkinje cell. The approaching to pathologi-
cal area in the peripheral zone of substrate (e and f), myofibrillar disorganization, citoplas-
mic vacuolization, swelling and disappearance of mitochondrial crests, myofibrillar rests and 
remains of erythrocytes were observed. The (h) and (i) corresponds to the central zone showing 
strong vacuolization and cell destruction and myofibrillar residue. Fat replacement, lympho-
cytic infiltration, Chagasic myocarditis, collagen tissue or apoptotic bodies were not observed.
It is important to note that when we approach to pathological areas progressive cell damage 
was observed. In the central zone of substrate low voltage systolic EGMs coincided with strong 
cell destruction and cytoplasmic disorganization. The peripheral zone of substrate with cell 
damage, mitochondrial swelling and myofibrillar residue without apoptotic bodies coincided 
with late potentials, diastolic and/or presystolic activity (Figures 2 and 3). These findings 
support mitochondrial energy loss as possible non-apoptotic progressive tissue damage and 
death cell. Our results suggest the interesting possibility that substrate could be generated by 
an abnormal expression of neural crest cells localized in RVOT during cardiac development. 
Because an epicardial and endocardial substrate was demonstrated, our findings together 
with those of other researchers support the probability of a transmural substrate.
7. Mechanisms of arrhythmias
Two theories suggest that an abnormal repolarization (local re-excitation by phase 2 reentry in 
the epicardium) or a defect of the depolarization (disturbances in depolarization of RVOT can 
cause conduction delay) may be responsible of phenotype and VF in BrS [40–43]. However, 
in BrS the arrhythmias are usually polymorphic VT or VF, and these cannot be supported by 
macro-reentry mechanisms. VF depends of a firing focus initiated by early or delayed after-
depolarization or a micro-re-entry [44]. Surviving cells surrounded by fibrosis has demon-
strated to be responsible of slow conduction and reentry in inhomogeneous scars [45]. The 
residual electrical activity within scar was reported as delayed or isolated EGMs, late potentials 
or diastolic EGMs and their elimination during sinus rhythm was effective to prevent VT/VF 
[45]. In peripheral zone of substrate when a sufficient degree of cell damage was reached such 
as we found with TEM and resting potentials are reduced the polymorphic VT/VF may occur. 
This event could be originated through a firing focus or by multiple wavelets from a reentrant 
microcircuit, and would explain the “diastolic electrical activity” observed in our patients.
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In addition, we found pre-systolic potentials as was previously reported by Haissaguerre 
et al. [15]. As show Figure 8, the Purkinje fibers in RVOT could be involved in the origin of 
pre-systolic potentials and in genesis of early-onset PVCs that can trigger VT or VF, by spon-
taneous depolarization or micro-reentry circuit in the Purkinje network [30].
8. Conclusion
In patients with BrS of high risk the substrate RFA may be a potential option of treatment. We 
successfully ablated the substrate of BrS from the endocardium based on the electrophysiologi-
cal and ultrastructural findings. Our data together with the observations of other researchers 
suggest a transmural substrate, contributing to future definition of the arrhythmogenic sub-
strate in BrS. As many phenotypes are involved in BrS, it is not unthinkable that different sub-
strates may exist in BrS. ECG analysis during administration of a sodium channel blocker allows 
approximately determined the size and location of substrate. Careful endocardial mapping 
allows identify late potentials, presystolic and diastolic EGMs as a new risk marker to guide 
an endocardial substrate RFA, probably with the same results what a more complex epicardial 
ablation. A comparative study between endocardial and epicardial RFA should be performed.
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